Clinical Trial Search

Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Change in Macular Thickness From Baseline to 6 Weeks Postoperatively After Cataract Surgery — 252.6; 253.1 Microns

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029

Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar

Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015

Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Post-operative Clinical Findings of Cystoid Macular Edema — 8.85; 8.95 mm

Primary: Central Retinal Thickness — 350 micrometers

Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants

Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters

Primary: Visual Acuity — 52 Units on a scale

Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Complete Resolution of Subretinal Fluid — 0 participants

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60; 31 Patients

Primary: Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks — .77; .61; .54 proportion of baseline retinal thickness — p=<0.0001

Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units

Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm

Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants

Primary: Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 4 Months — 13; 15 microns

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Anterior Chamber Cell Grade — 67; 18 Participants

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…